Biomedical subjects

B Brkić

Publications and source records attributed to B Brkić.

9 recordsLinked to original sources

PubMed2000

Effect of centrally administered somatostatin on pituitary thyrotropes in male rats.

The effects of intracerebroventricularly administered somatostatin (SRIH-14 or -28) on growth and function of pituitary thyrotropes (TSH-cells) were examined in adult male Wistar rats. The animals were implanted with an intracerebroventricular cannula and after a recovery period, administered three 1 microg doses of SRIH-14 or -28 dissolved in 5 microl saline every second day. Controls were treated in the same way with the same volume of saline only. TSH-producing cells were studied using the peroxidase-antiperoxidase immunohistochemical procedure. Blood samples were collected for hormone (TSH) analyses 5 days after the last injection. Both SRIH-treatments significantly decreased (p < 0.05) all morphometric parameters obtained for TSH-cells in comparison with controls. The volume of TSH-cells decreased by 27%, nuclei by 44% and volume density by 33% in animals treated with SRIH-14. In animals treated with SRIH-28, these parameters were also significantly decreased (p < 0.05) (22%, 31%, and 25% respectively) compared to control rats. Serum concentrations of TSH were significantly decreased (p < 0.05) by 15% in SRIH-14- and by 12% in SRIH-28-treated animals in comparison with the controls. These observations suggest that centrally administered SRIH- 14 or -28 is specifically involved in the control of growth and secretory activity of TSH cells.

Animals↗

PubMed2000

Effects of centrally applied somatostatin on pituitary adrenocorticotropes in female rats.

Effects of intracerebroventricular (i.c.v.) application of somatostatin (SRIH-14 or SRIH-28) on growth and function of pituitary adrenocorticotropes (ACTH cells) were examined in adult female Wistar rats. Animals were subjected to i.c.v. administration of three 1-microg doses of SRIH-14 or SRIH-28 dissolved in 5 microl saline every second day. Controls were treated in the same way with the same volume of saline only. ACTH-producing cells were studied using the peroxidase-antiperoxidase (PAP) immunohistochemical procedure; blood samples were collected for hormone analyses 5 days after the last injection. SRIH-28 treatment decreased (p < 0.05) all morphometric parameters compared to control rats. Volume of ACTH cells decreased by 10%, nuclei by 36% and volume density by 13%. No significant changes (p > 0.05) in these parameters occurred after SRIH-14 treatment. Plasma concentration of ACTH in SRIH-28-treated rats was significantly lower (p < 0.05) than in control rats by 35%. In SRIH-14-treated rats, plasma concentration of ACTH was slightly, but not significantly (p > 0.05) increased by 13% compared to saline treatment. These observations suggest that centrally administered somatostatin-28, but not somatostatin-14, is specifically involved in the control of growth and secretory activity of ACTH cells in female rats. Thus, selective pharmacological manipulation of SRIH-28 receptors reached from CSF may affect ACTH activity without altering actions usually attributed to receptors sensitive to SRIF-14.

Adrenocorticotropic Hormone↗

PubMed1998

Morphometric and functional changes of rat pituitary somatotropes and lactotropes after central administration of somatostatin.

This study examined effects of intracerebroventricularly (i.c.v.) administered somatostatin (SRIH-14 and SRIH-28) on growth and function of pituitary somatotropes (GH cells) and lactotropes (PRL cells). Male rats received three i.c.v. injections (1 microgram/5 microliters) of SRIH-14 or SRIH-28 every second day. Blood samples were collected for hormone assays and pituitaries were removed for histological and morphometric evaluation 5 days after the last i.c.v. treatment. Compared to control animals, SRIH treatment decreased (p < 0.05) pituitary weight and all morphometric measurements obtained in GH and PRL cells. Concentrations of serum growth hormone (GH) and prolactin (PRL) in both SRIH-treated groups were also lower (p < 0.05) than in control rats. These findings suggest that centrally administered somatostatin is specifically involved in the control of growth and secretory activity of GH and PRL cells. Thus, pharmacological manipulation of SRIH receptors reached from cerebrospinal fluid may alter systemic effects of GH and PRL.

Animals↗

PubMed1996

Inhibitory effects of centrally administered somatostatin on the adrenal zona glomerulosa in male rats.

This study examined the effects of intracerebroventricularly administered somatostatin (SRIF-28 and SRIF-14) on growth and steroidogenic capacity of the rat adrenal zona glomerulosa. Male adult Wistar rats were subjected to intracerebroventricular administration of three 1 microgram doses of SRIF-28 or SRIF-14 every other day. Five days after the last dose, the rats were sacrificed by decapitation. Blood samples were collected for hormonal analyses, and left adrenal glands were taken for histological and morphometric evaluation. In comparison with control animals, the SRIF-treated rats had decreased (p < 0.05) adrenal gland weight and volume. Stereological and morphometric analyses showed decreased (p < 0.05) absolute and relative volumes of the cells and nuclei only in the zona glomerulosa. The plasma levels of aldosterone, growth hormone, and prolactin in both SRIF-treated groups were lower (p < 0.05) than in the control group. The levels of adrenocorticotropic hormone after SRIF treatment did not differ significantly from those in control rats. These findings suggest that centrally administered somatostatin is specifically involved in the control of zona glomerulosa growth and secretion; this effect is probably mediated by inhibiting the secretion of the corresponding pituitary hormones.

Aldosterone↗

PubMed1970